Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Thomas Mika¹, Katharina Strate¹, Swetlana Ladigan¹, Clemens Aigner², Uwe Schlegel³, Iris Tischoff⁴, Sabine Tischer-Zimmermann⁵, Britta Eiz-Vesper⁴, Britta Maecker-Kolhoff⁶* and Roland Schroers¹*

¹ Department of Medicine, Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany; ² Department of Thoracic Surgery, Ruhlandklinik, University Hospital Essen, Essen, Germany; ³ Department of Neurology, Ruhr-University Bochum, Bochum, Germany; ⁴ Department of Pathology, Ruhr-University Bochum, Bochum, Germany; ⁵ Institute for Transfusion Medicine, Hannover Medical School, Hanover, Germany; ⁶ Department of Pediatric Hematology and Oncology, Hannover Medical School, Hanover, Germany

*Correspondence: Britta Maecker-Kolhoff, Maecker-Kolhoff.Britta@mh-hannover.de
Roland Schroers, Roland.Schroers@rub.de

Specialty section: This article was submitted to Hematology, a section of the journal Frontiers in Medicine

Received: 06 October 2019
Accepted: 29 November 2019
Published: 18 December 2019

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory PTLD are scarce. Today, there is no consensus how to treat rituximab-refractory PTLD, especially in highly aggressive disease. Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined brentuximab vedotin and third-party EBV-specific T-cells in a multidisciplinary treatment approach.

Keywords: PTLD, alloHSCT, aggressive lymphoma, brentuximab vedotin (BV), third-party EBV-specific T-lymphocytes

BACKGROUND

Post-transplant lymphoproliferative disease (PTLD) is a rare and serious complication after allogeneic hematopoietic stem cell transplantation (alloHSCT). PTLD is often linked to Epstein-Barr virus (EBV) infection or reactivation. It comprises a heterogeneous group ranging from polyclonal non-destructive to aggressive non-Hodgkin and Hodgkin-like disorders (1, 2). Previous studies have provided further insight into the nature and management of PTLD following alloHSCT (2, 3). During the past few years, survival rates of PTLD have improved, mainly due to the introduction of rituximab (1–3). However, reports on curative management of refractory PTLD are scarce.
Adoptive immunotherapy with EBV-specific T-lymphocytes directed against PTLD has shown promising results in different clinical trials (1, 2, 4). Furthermore, brentuximab vedotin (BV), a CD30-directed antibody-toxin conjugate, represents an attractive therapeutic approach due to CD30-expression in a subgroup of PTLD that is probably induced by EBV infection (1, 5). BV was clinically active in two studies on diffuse large B-cell lymphoma (DLBCL) with complete remission (CR) rates of 17 and 58%, respectively (6, 7). Currently, there is only limited reporting on the therapeutic application of BV in PTLD (8).

Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined BV and third-party EBV-specific T-cells in a multidisciplinary treatment approach.

**CASE PRESENTATION – DESCRIPTION OF TESTS AND THERAPY**

In November 2015, a 52-year-old man presented with acute myeloid leukemia. Five years earlier, the patient had been treated with azathioprine for chronic inflammatory bowel disease (CIBD). Induction chemotherapy for AML comprised two cycles of cytarabine (700 mg/m²) and daunorubicine (180 mg/m²) and resulted in complete remission (CR). Following both cycles of the initial chemotherapy, the patient developed severe infections in neutropenia, requiring extensive antibiotic and antifungal treatments.

The patient, who had AML in the intermediate-risk group according to European Leukemia Network (ELN) criteria, underwent alloHSCT following reduced-intensity conditioning with fludarabine (150 mg/m²) and treosulfan (30 g/m²) in the first CR. Graft-versus-Host disease (GvHD) prophylaxis consisted of ATG-F (60 mg/kg), methotrexate, and ciclosporine. Prior to alloHSCT, the patient was EBV-IgG and CMV-IgG seropositive; he received peripheral blood stem cells collected from this partially (8/10) HLA-matched third-party donor was prepared (alloCELL@mh-hannover.de). As previously described, the in vitro-selection of highly active EBV-specific T-lymphocytes is based on interferon-γ release following stimulation with EBNA-peptide pools (9, 10). Clinical-grade EBV-specific T-cells were enriched twice from the same third-party donor, using the overlapping peptide pools PepTivar EBV-EBNA1 and the HLA-restricted peptide pool PepTivar EBV-Select-in. The purities of the T-cell products were 47 and 46% CD3+IFN-γ+ T-cells, respectively. Two weeks after the first BV infusion, a first dosage of EBV-specific T-cells derived from this partially (8/10) HLA-matched third-party donor was administered (Supplementary Table 1).

Recognizing the dismal prognosis of R-CHOP refractory DLBCL and the patient’s impaired physical condition (ECOG 2-3), we decided against intensive second-line chemotherapy and started treatment with BV (1.8 mg/kg, monthly). At the same time, adoptive immunotherapy with third-party EBV-directed T-lymphocytes was prepared (alloCELL@mh-hannover.de). As previously described, the in vitro-selection of highly active EBV-specific T-lymphocytes is based on interferon-γ release following stimulation with EBNA-peptide pools (9, 10). Clinical-grade EBV-specific T-cells were enriched twice from the same third-party donor, using the overlapping peptide pools PepTivar EBV-EBNA1 and the HLA-restricted peptide pool PepTivar EBV-Select-in. The purities of the T-cell products were 47 and 46% CD3+IFN-γ+ T-cells, respectively. Two weeks after the first BV infusion, a first dosage of EBV-specific T-cells derived from this partially (8/10) HLA-matched third-party donor was administered (Supplementary Table 1).

After two courses of BV and EBV-directed T-cells, shrinkage of the lung tumors was observed in CT. Interpreting the agonizing cough and persistent dyspnea to be primarily caused by a left pulmonary lymphoma mass (Figure 1C), an individualized decision for surgery was made, and the patient underwent thoracotomy with left lower lobectomy, resulting in symptom relief. One month after chest surgery, the patient complained of increasing headaches and dizziness. Demonstration of a single enhancing lesion on brain MRI (Supplementary Figure 2) together with PCR-detection of EBV-DNA in the CSF was highly suggestive of a cerebral PTLD manifestation (biopsy refused by patient). Radiotherapy (40 Gy) was applied to the cerebral lesion.

In summary, between October 2016 and November 2017, the patient was treated with 12 courses of BV, six courses of EBV-specific T-lymphocytes, and monthly infusions of polyclonal immunoglobulins. The performance status improved continuously, and symptoms of pulmonary as well as CNS manifestations resolved completely 5 months after chest surgery and radiotherapy. Except for mild sensory polyneuropathy, the patient developed no side effects. One year following the initial PTLD diagnosis, staging by PET-CT and cMRI demonstrated CR of all disease manifestations (Figure 1D, Supplementary Figure 1B). Nearly 4 years after the initial
FIGURE 1 | Computed tomography (CT), chest. (A) Disseminated atypical pulmonary infiltrates (day +145 after alloHSCT), (B) Chest CT following antimycotic therapy (day +170), (C) Disease progression after three courses of rituximab and two courses R-GHOP (day +228), (D) Complete remission (CR) after five courses of brentuximab vedotin and three courses of third-party EBV-specific T-cells.

diagnosis of AML and 3.5 years after the occurrence of PTLD, the patient remains free of hematologic disease.

DISCUSSION

Following alloHSCT for hematologic disease, up to 11% of patients develop PTLD, with histopathology demonstrating DLBCL in ~50% of the cases (2, 3, 11). In accordance with established risk factors (3, 11), our patient was older than 40 years and had undergone MUD transplantation in serological EBV-mismatch. Further, the patient’s history of CIBD including azathioprine treatment added to the risk of PTLD by augmented immunosuppression. The risk of PTLD in this situation was significantly enhanced by in vivo T-cell depletion by ATG treatment. Although significant EBV DNAemia was detected at days +88 and +111, respectively, we went without preemptive rituximab, taking into consideration the spontaneous EBV-DNA decline to <5 EBV copies/ml, cessation of immunosuppressives, initial absence of clinical correlates, and increased risk of recurrent opportunistic infections.

In our patient, the rapid onset and deterioration of PTLD symptoms and the non-responsiveness to rituximab, which has been reported in 30-50% of post-alloHSCT PTLD (2, 4, 11), characterized the highly aggressive PTLD course. Even polychemotherapy was ineffective, and, only after administration of the CD30-directed immunotoxin BV disease control could be achieved. Of note, significant CD30 co-expression is observed in up to 85% of PTLD subtypes (5), making CD30 an attractive target in PTLD (1). Despite initial promising results with a 70% CR rate in PTLD (6, 7), advanced clinical trials of BV in this particular situation have not yet been reported. More importantly, the long-term efficacy of monotherapy with BV in CD30+ DLBCL arising from PTLD is undetermined.

EBV-associated PTLD is the result of impaired anti-viral T-cell activity following alloHSCT. EBV-specific cytotoxic lymphocytes (CTL) are capable of inducing strong EBV-specific cellular immune response. In the past, in vitro-expanded EBV-specific CTL have been infused as part of different therapeutic strategies, using both autologous and allogeneic CTL (10, 12, 13). In addition, new approaches have been developed, including the adoptive transfer of third-party virus-specific T-lymphocytes (9, 13). This approach enables T-cell generation by stimulation and selection with overlapping viral peptides (10) without the time-consuming procedure of in vitro-culture of CTL. Furthermore, EBV-specific T-lymphocytes can be collected from third-party donors in the situation of EBV-negative stem cell donors, as outlined in this case report. Here, it was possible to identify an adequately HLA-matched third-party donor from the alloCELL.
registry within 24 h and to verify donor eligibility within 3 days. Production of EBV-specific T-cells could be initiated within 2 weeks, and the patient received a total of six infusions from two production runs over a period of 8 months.

In conclusion, we report the first case of long-term control (cure) of highly aggressive EBV-PTLD including cerebral disease by combined brentuximab vedotin (BV) and adoptive EBV-specific T-cell therapy. We postulate that both rapid disease control by BV and also restoration of EBV-specific T-cell immunity were crucial components of our approach. Indeed, EBV-specific T-lymphocytes could be detected in the patient’s peripheral blood one year after the last application of third-party T-cells. T cells were directed against the EBV-derived antigens used in the manufacturing process (EBNA-1, EBV-select) as well as unrelated antigens (LMP-2a), suggesting epitope spreading as part of an endogenous immune response. Considering 2-year overall survival rates of <50% (4, 11), rituximab-refractory PTLD poses a significant target for future clinical research. Various approaches, such as adoptive immunotherapy with virus-specific or chimeric antigen receptor (CAR) T-cells and also novel agents including brentuximab, have been suggested (1). However, today, there is no consensus on how to treat rituximab-refractory PTLD, especially in highly aggressive disease. In our opinion, the favorable treatment outcome in the challenging situation of our patient warrants further studies of combined BV and third-party EBV-specific T-cells in CD30+ EBV-associated PTLD.

DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the article/Supplementary Material.

ETHICS STATEMENT
Written informed consent was obtained from the participant for the publication of this case report.

AUTHOR CONTRIBUTIONS
TM, CA, US, IT, ST-Z, and RS collected the data and prepared the figures and tables. TM, KS, SL, BE-V, BM-K, and RS wrote the manuscript.

ACKNOWLEDGMENTS
We acknowledge support by the DFG Open Access Publication Funds of the Ruhr-Universität Bochum.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2019.00295/full#supplementary-material
REFERENCES

1. Al Hamed R, Bazarbachi AH, Mohy M. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transplant. (2019). doi: 10.1038/s41409-019-0548-7. [Epub ahead of print].

2. Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. *N Engl J Med.* (2018) 378:549–62. doi: 10.1056/NEJMra1702693

3. Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, et al. EBV-associated post-transplant lymphoproliferative disorder following *in vivo* T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. *Bone Marrow Transplant.* (2014) 49:280–6. doi: 10.1038/bmt.2013.170

4. DeStefano CB, Desai SH, Shenoy AG, Catlett JP. Management of post-transplant lymphoproliferative disorders. *Br J Haematol.* (2018) 182:330–43. doi: 10.1111/bjh.15263

5. Vase MO, Maksten EF, Bendix K, Hamilton-Dutoit S, Andersen C, Moller MB, et al. Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders. *Leukemia Lymphoma.* (2015) 56:1677–85. doi: 10.3109/10428194.2014.966242

6. Gandhi M, Ma S, Smith SM, Nabhan C, Evens AM, Winter JN, et al. Brentuximab vedotin (BV) plus rituximab (R) as frontline therapy for patients (Pts) with epstein barr virus (EBV)+ and/or CD30+ lymphoma: phase i results of an ongoing phase I-II study. *Blood.* (2014) 124:3096. doi: 10.1182/blood.V124.21.3096.3096

7. Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. *Blood.* (2015) 125:1394–402. doi: 10.1182/blood-2014-09-598763

8. Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, et al. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review. *Crit Rev Oncol Hematol.* (2017) 109:42–50. doi: 10.1016/j.critrevonc.2016.11.009

9. Schulze-Florey RE, Tischer S, Kuhlmann L, Hundsdorfer P, Koch A, Anagnostopoulos I, et al. Dissecting epstein-barr virus-specific T-cell responses after allogeneic EBV-specific T-cell transfer for central nervous system posttransplant lymphoproliferative disease. *Front Immunol.* (2018) 9:1475. doi: 10.3389/fimmu.2018.01475

10. Eiz-Vesper B, Maeccker-Kolhoff B, Blasczyk R. Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry. *Front Immunol.* (2012) 3:3410. doi: 10.3389/fimmu.2012.00410

11. Garcia-Cadenas I, Yanez L, Jarque I, Martino R, Perez-Simon JA, Valcarcel D, et al. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). *Eur J Haematol.* (2019) 102:465–71. doi: 10.1111/ejh.13226

12. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, et al. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. *J Clin Oncol.* (2013) 31:39–48. doi: 10.1200/JCO.2011.39.8495

13. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. *Blood.* (2007) 110:1123–31. doi: 10.1182/blood-2006-12-063008

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Mika, Strate, Ladigan, Aigner, Schlegel, Tischoff, Tischer-Zimmermann, Eiz-Vesper, Maeccker-Kolhoff and Schroers. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.